Given that dysregulation of sphingolipid metabolism is also present in other hematopoietic malignancies and solid tumors, this novel feedback mechanism may also be applicable to the interaction between SPHK1 and other tumor drivers. This evidence concerns the gene SPHK1 and neoplasm.